Posted by Michael Wonder on 26 Dec 2020
Novadip Biosciences receives rare paediatric disease priority review and orphan disease designation
23 December 2020 - Novadip Biosciences today announces that the U.S. FDA has granted rare paediatric disease designation and Orphan Drug designation for NVD‑003, a cell therapy for the treatment of congenital pseudarthrosis of the tibia, a rare but serious and debilitating condition, that primarily affects children with devastating consequences.
NVD-003, Novadip’s lead product candidate, is a clinical-stage investigational cell-based therapy and a new paradigm in regenerative medicine.
